Abbott RealTime CT/NG Assay with Modified Formulation that Detects the Chlamydia trachomatis Variant Containing a 377 bp Cryptic Plasmid Deletion

Wednesday, March 12, 2008
Continental Ballroom
Shiaolan Y. Ho, PhD , Abbott Molecular, Des Plaines, IL
Barbara Van Der Pol, PhD, MPH , Marion County Health Department, Indianapolis, IN
James A. Williams, BS, Microbiology , Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN
Amy D. Pantone, BS , Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN
Jie Lai-Zhang , Abbott Molecular, Des Plaines, IL
Erika M. Webb , Abbott Molecular, Des Plaines, IL
Catherine P. Barry , Abbott Molecular, Des Plaines, IL
Won S. Choi , Abbott Molecular, Des Plaines, IL
Klara Abravaya , Abbott Molecular, Des Plaines, IL
John M. Robinson , Abbott Molecular, Des Plaines, IL

Background:
A new variant of Chlamydia trachomatis (nvCT) containing a 377 bp deletion in cryptic plasmid was reported in Sweden in late 2006. nvCT accounts for about 10 to 70% of the CT positive cases in certain counties in Sweden. The deleted region includes the CT primer binding sites for the Abbott RealTime CT/NG and CT assays.

Objective:
We have developed a modified formulation of the Abbott RealTime CT/NG and CT assays to detect nvCT. The modified formulation includes an additional set of CT primers and probe targeting a region of the cryptic plasmid outside the deletion. The performance of the modified formulation was compared to that of the original formulation and the Aptima Combo 2 (Gen-Probe) assay.

Method:
250 urine samples were collected and tested per manufacturer's instructions.

Result:
For Chlamydia trachomatis (CT), the two Abbott formulations agreed on 36/36 positives and 212/214 negatives. For Neisseria gonorrhoeae (NG), the two formulations agreed on 11/11 positives and 239/239 negatives. The performance concordance was also compared between the Abbott RealTime CT/NG assay with modified formulation and the Aptima Combo 2 assay. For CT, the two assays agreed on 37/41 positives and 208/209 negatives. There were 4 unique Gen-Probe positives and 1 unique Abbott positive. For NG, the two assays agreed on 11/11 positives and 239/239 negatives.

Conclusion:
Both the original and modified formulations of the Abbott RealTime CT/NG and CT assays provide sensitive and specific methodology for detection of CT and NG.

Implications:
A modified formulation of the Abbott RealTime CT/NG and CT assays has been developed for detection of nvCT.
(Product in development. Not available in the US.)
See more of: Poster Session 2
See more of: Oral and Poster